NCT06842823 - A Study of Navenibart in Participants With Hereditary Angioedema | Biotech Hunter

Enrollment

145

Participants

Timeline

Start Date

March 20, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

September 30, 2027

Conditions

Hereditary Angioedema (HAE)

Interventions

DRUG

navenibart

Navenibart will be administered as a subcutaneous injection.

DRUG

Placebo

Placebo will be administered as a subcutaneous injection.

Trial Locations (29)

1680

RECRUITING

Site 28, Sofia

7700

RECRUITING

Site 21, Cape Town

17036

RECRUITING

Site 15, Hummelstown

20902

RECRUITING

Site 6, Wheaton

33613

RECRUITING

Site 25, Tampa

35209

RECRUITING

Site 9, Birmingham

43617

RECRUITING

Site 12, Toledo

45236

RECRUITING

Site 7, Cincinnati

48202

RECRUITING

Site 13, Detroit

63141

RECRUITING

Site 10, St Louis

72205

RECRUITING

Site 3, Little Rock

80112

RECRUITING

Site 8, Centennial

80907

RECRUITING

Site 11, Colorado Springs

85251

RECRUITING

Site 2, Scottsdale

90404

RECRUITING

Site 4, Santa Monica

92122

RECRUITING

Site 26, San Diego

94598

RECRUITING

Site 1, Walnut Creek

92123,

RECRUITING

Site 14, San Diego

K1H 1E4

RECRUITING

Site 5, Ottawa

AB T6G 2B7

RECRUITING

Site 23, Edmonton

Unknown

RECRUITING

Site 20, Hong Kong

RECRUITING

Site 27, Amsterdam

35-051

RECRUITING

Site 29, Rzeszów

PL6 8HD

RECRUITING

Site 18, Plymouth

NW3 2QG

RECRUITING

Site 24, Hampstead

BS10 5N

RECRUITING

Site 19, Bristol

CB2 0QQ

RECRUITING

Site 16, Cambridge

GU16 7UJ

RECRUITING

Site 22, Frimley

E1 2ES

RECRUITING

Site 17, London